Vertex Pharmaceuticals (VRTX)
498.72
+37.85 (8.21%)
NASDAQ · Last Trade: Mar 10th, 3:46 PM EDT
The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry darlings. As of March 10, 2026, the industry is processing a tale of two trajectories: Vertex Pharmaceuticals (NASDAQ: VRTX) has cemented
Via MarketMinute · March 10, 2026
Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER trial. The data, which focused on povetacicept for the treatment of IgA nephropathy (IgAN), showcased a 52% reduction in proteinuria, a
Via MarketMinute · March 10, 2026
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.chartmill.com
Via Chartmill · March 10, 2026
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakoutchartmill.com
Via Chartmill · February 28, 2026
Which S&P500 stocks are moving on Tuesday?chartmill.com
Via Chartmill · March 10, 2026
Top S&P500 movers in Tuesday's pre-market sessionchartmill.com
Via Chartmill · March 10, 2026
Data from Stocktwits indicated that retail sentiment on SPY and QQQ was stabilizing.
Via Stocktwits · March 10, 2026
The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.
Via Stocktwits · March 9, 2026
The company has performed well over the long run.
Via The Motley Fool · March 8, 2026
Both of these players are leaders in their fields.
Via The Motley Fool · March 5, 2026
These two biotechs have a lot in common. Their differences are even more pronounced.
Via The Motley Fool · March 4, 2026
CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.
Via The Motley Fool · March 2, 2026
Patience should pay off with these two healthcare giants.
Via The Motley Fool · February 26, 2026
One of these is not like the other.
Via The Motley Fool · February 26, 2026
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total transaction value of up to $2.4 billion. The deal centers on Orna’s proprietary circular RNA (oRNA)
Via MarketMinute · February 25, 2026
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market.
But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
Via StockStory · February 24, 2026
This biotech powerhouse could maintain its strength for the long term.
Via The Motley Fool · February 24, 2026
Even a great stock has a ceiling.
Via The Motley Fool · February 22, 2026
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Via The Motley Fool · February 20, 2026
Via MarketBeat · February 19, 2026
Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from recently launched products in hematology and pain management. Management pointed to disciplined commercial execution and progress in diversifying the revenue base as key themes. CEO Reshma Kewalramani highlighted, “We are well positioned to deliver on the significant opportunities in front of us and drive sustained growth over the long term.” The company credited successful new product launches—particularly in international markets—and deeper penetration across age groups and geographies for cystic fibrosis as primary revenue drivers.
Via StockStory · February 19, 2026
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · February 18, 2026
Vertex has the revenue power to excel during any market environment.
Via The Motley Fool · February 18, 2026
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based biotechnology pioneer is now fighting to prove that its messenger RNA (mRNA) platform is a "one-hit wonder" no more. The company has dominated recent financial [...]
Via Finterra · February 17, 2026
In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly "sweetened" revised bid for Ocular Therapeutix (NASDAQ: OCUL). The updated offer comes at a high-stakes moment for the biotech industry, as Ocular Therapeutix
Via MarketMinute · February 16, 2026